Baseline demographic and disease characteristics of patients with and without dactylitis
| With dactylitis at baseline | Without dactylitis at baseline | |||||
|---|---|---|---|---|---|---|
| Placebo | Guselkumab | Total | Placebo | Guselkumab | Total | |
| Patients, n | 23 | 58 | 81 | 26 | 42 | 68 |
| Age, years | 37.8 ± 10.3 | 45.2 ± 13.3 | 43.1 ± 12.9 | 49.8 ± 11.5 | 50.5 ± 11.7 | 50.2 ± 11.5 |
| Male | 8 (34.8) | 33 (56.9) | 41 (50.6) | 16 (61.5) | 19 (45.2) | 35 (51.5) |
| Weight, kg | 86.1 ± 20.5 | 82.6 ± 19.0 | 83.6 ± 19.3 | 86.5 ± 21.0 | 86.8 ± 24.4 | 86.7 ± 23.0 |
| SJC (0–66) | 10.6 ± 6.1 | 14.0 ± 8.1 | 13.1 ± 7.7 | 10.5 ± 8.7 | 9.1 ± 5.7 | 9.6 ± 7.0 |
| TJC (0–68) | 22.5 ± 14.4 | 22.7 ± 11.7 | 22.6 ± 12.4 | 18.0 ± 10.3 | 18.0 ± 12.4 | 18.0 ± 11.6 |
| CRP, mg/dL | 1.9 ± 2.1 | 2.2 ± 2.7 | 2.1 ± 2.5 | 1.8 ± 2.6 | 1.3 ± 2.0 | 1.5 ± 2.3 |
| HAQ-DI | 1.36 ± 0.46 | 1.48 ± 0.59 | 1.44 ± 0.56 | 1.32 ± 0.61 | 1.34 ± 0.66 | 1.33 ± 0.64 |
| PsA duration, years | 4.7 ± 5.3 | 5.7 ± 5.6 | 5.4 ± 5.5 | 8.8 ± 8.2 | 8.7 ± 8.8 | 8.8 ± 8.5 |
| Patients with dactylitis | 23 (100) | 58 (100) | 81 (100) | 0 | 0 | 0 |
| Dactylitis score | 3.9 ± 3.0 | 6.5 ± 6.2 | 5.7 ± 5.5 | – | – | – |
| Patients with enthesitis | 14 (60.9) | 45 (77.6) | 59 (72.8) | 17 (65.4) | 31 (73.8) | 48 (70.6) |
| Enthesitis score | 1.7 ± 1.8 | 2.0 ± 1.6 | 1.9 ± 1.7 | 1.7 ± 1.7 | 2.1 ± 2.0 | 1.9 ± 1.9 |
| BSA, % | 11.6 ± 9.8 | 18.0 ± 16.7 | 16.2 ± 15.3 | 15.3 ± 14.5 | 16.3 ± 14.0 | 15.9 ± 14.1 |
| PASI (0–72) | 9.6 ± 8.8 | 12.3 ± 10.8 | 11.6 ± 10.3 | 10.1 ± 7.3 | 11.7 ± 10.2 | 11.1 ± 9.2 |
| Previous anti-TNF therapy | 1 (4.3) | 5 (8.6) | 6 (7.4) | 3 (11.5) | 5 (11.9) | 8 (11.8) |
| Baseline medication use | ||||||
| MTX | 8 (34.8) | 25 (43.1) | 33 (40.7) | 11 (42.3) | 22 (52.4) | 33 (48.5) |
| Oral corticosteroids | 4 (17.4) | 7 (12.1) | 11 (13.6) | 4 (15.4) | 5 (11.9) | 9 (13.2) |
| NSAIDs | 16 (69.6) | 38 (65.5) | 54 (66.7) | 20 (76.9) | 32 (76.2) | 52 (76.5) |
Data presented as n (%) or mean ± SD unless otherwise noted.
BSA, body surface area; CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor.